GeoVax Labs, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GeoVax Labs, Inc.
Viking’s Phase IIb NASH Data Provide Across-The-Board Success
Competing with Madrigal in the THRβ agonist class in non-alcoholic steatohepatitis, Viking’s VK2809 reports stronger efficacy and better safety and tolerability than resmetirom at that stage.
ICER’s NASH Panel Shows Some Enthusiasm For Resmetirom, None For OCA
The cost-effectiveness group voted by a slight margin that Madrigal’s non-alcoholic steatohepatitis drug offers benefit above lifestyle changes alone, but decisively that Intercept’s candidate does not.
‘Leaps of Faith:’ ICER Meeting Suggests Reimbursement Hurdles For NASH Drugs
Lack of long-term clinical outcomes data on a slowly progressing, common condition combined with a rapidly changing treatment space for obesity and health system cost issues may present problems for two NASH treatments even if they win accelerated approval from US FDA.
Early Data For GeoVax COVID-19 Vaccine Point To Efficacy In Immunocompromised Population
The company unveiled antibody and T-cell responses in patients with blood cancers and also plans to explore GM-CM04S1 in additional immunocompromised populations, such as lupus patients.
- Drug Delivery
- Other Names / Subsidiaries
- Dauphin Technology, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.